Press Release   |   Aug 23, 2022

VectorBuilder supports first gene therapy trial for Menkes disease

The father holding his patient son, and key team members from VectorBuilder, Lantu Biopharma and the hospitals physicians right after drug administration.

August 23, 2022, VectorBuilder Inc. – a global leader in gene delivery technologies – has announced that its partnership with cell and gene therapy company Lantu Biopharma has led to the first human trial of an innovative gene therapy drug candidate for Menkes disease. The adeno-associated virus (AAV) based drug, LTGT06, was developed by Lantu with crucial support from VectorBuilder. The trial subject was a three-year-old boy whose father gained worldwide attention for not giving up on his son.

Xu Haoyang from China’s Yunan province was less than a year old when diagnosed with Menkes disease, a congenital disorder arising from mutations in the ATP7A gene. Patients show severe neurological defects and typically do not live beyond three years. There is currently no cure for Menkes.

To save his son, Haoyang’s father Xu Wei, who has a high school education, taught himself chemistry and biology to build a home laboratory to synthesize copper histidine, a chemical shown to reduce Menkes symptoms but is not available in China. The father’s story of love and determination made international news while also generating debate over DIY medicine.

VectorBuilder formed a partnership with Lantu to develop AAV-based drug candidates for Menkes, providing CRO and CDMO services including AAV vector design and optimization, and clinical-grade AAV manufacturing. Lantu studied the efficacy and safety of the candidates and collaborated with 920 Hospital and Hope of Health Hospital in Kunming to perform an investigator-initiated trial (IIT) to test the lead candidate, LTGT06, on Haoyang. After receiving official approval, the drug was administered shortly after the boy’s third birthday this year.

Xu Wei said: “I knew that copper histidine can only slow down Menkes, and gene therapy is the only hope for reversing the disease. We are now beginning to notice improvements. I am so grateful to see Haoyang’s condition improve for the first time in three years rather than deteriorating. I am hopeful he will continue to get better." 

VectorBuilder’s Chief Scientist Dr. Bruce Lahn commented: “VectorBuilder has supported gene therapy programs for many pharma and biotech companies along their entire pipelines, from early-stage R&D all the way to CDMO manufacturing. I am very pleased that we can play a role in the development of LTGT06. It is a testament to our technical capabilities and comprehensive end-to-end service capacity in the gene delivery space.”

Disclaimer: VectorBuilder does not recommend DIY medicine. We recommend that patients and their guardians seek the guidance of medical professionals for their treatment options.

About VectorBuilder Inc.

VectorBuilder is a global leader in gene delivery technologies. As a trusted partner in thousands of labs and biotech/pharma companies around the world, VectorBuilder is a one-stop shop for the design, development and optimization of gene delivery solutions from basic research to clinical applications. Its award-winning Vector Design Studio is a transformative innovation that allows researchers to easily design and order custom vectors online, freeing them from the tedious work of cloning and packaging vectors in the lab. The global company boasts high-throughput vector production capacity, vast vector and component inventories, one-on-one CRO solutions that include advanced AAV capsid engineering capabilities and state-of-the-art GMP facilities. With leading R&D and CDMO manufacturing capacity, the VectorBuilder team strives to provide the most effective gene delivery solutions and develop new tools for life sciences research and genetic medicine.

You can order various molecular cloning services through Design My Vector or Send Design Request on the homepage. You can find our available services and products on the menu bar.
Please let us know what you would like to hear from us about the latest technologies or discoveries by leaving a feedback or contacting us.